Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder
Status:
Unknown status
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
Currently, no study to date has directly tested a selective D1R agonist in relation to the
cognitive impairment of Schizophrenia without the confound of neuroleptics. The investigators
propose to examine the efficacy of DAR-0100A, a highly selective, full D1R agonist supported
by pre-clinical and preliminary pilot clinical data, in ameliorating the cognitive deficits
in Schizotypal Personality Disordered subjects receiving no medications including
antipsychotics.
The investigators hypothesize that 1) Baseline primary outcome measures will be impaired in
Schizotypal personality disorder (SPD) subjects compared to controls, 2) SPD subjects on
DAR-0100A will show improvement on primary measures greater than healthy controls and SPD
patients randomized to placebo, and 3) SPD patients will show significant improvements on
primary outcome variables on drug compared to placebo.